Journal
BLOOD
Volume 135, Issue 7, Pages 505-509Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019001859
Keywords
-
Categories
Funding
- University of Pennsylvania-Novartis Alliance
- EMD Serono Cancer Immunotherapy Clinical Fellowship by the Society for Immunotherapy of Cancer
- Bristol-Myers Squibb Oncology Fellowship in Clinical Cancer Research by the American Association for Cancer Research
- Gabrielle's Angel Foundation
- SIES-AIL fellowship by the Italian Society of Experimental Hematology
- Italian Leukemia Association
- National Institutes of Health, National Cancer Institute [1K99CA212302-01A1, R00CA212302]
- St. Baldrick's Foundation Scholar Award
- ASH Scholar Award
Ask authors/readers for more resources
Unintentional transduction of B-cell acute lymphoblastic leukemia blasts during CART19 manufacturing can lead to CAR19(+) leukemic cells (CARB19) that are resistant to CART19 killing. We developed an anti-CAR19 idiotype chimeric antigen receptor (alpha CAR19) to specifically recognize CAR19(+) cells. aCAR19 CAR T cells efficiently lysed CARB19 cells in vitro and in a primary leukemia-derived xenograft model. We further showed that alpha CAR19-CART cells could be used as an antidote to deplete CART19 cells to reduce long-term side effects, such as B-cell aplasia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
